The Syneos Health Podcast: Early Signals
di Syneos Health
Can We Redefine Cancer by Its Biology?
Informazioni su questo podcast
What are the signals today that will define the future of oncology treatment tomorrow?
The Syneos Health Podcast: Early Signals brings together leaders across biopharma, healthcare, academia and technology to explore the innovations reshaping drug development in oncology. Hosted by experts across Syneos Health, including Wael Harb, MD, Head of Research and Development and Scientific Strategy in oncology, each episode captures candid conversations about emerging science, evolving market dynamics and the trends poised to influence the future of patient care.
Tune in for timely perspectives on what's next—and what it means for the oncology industry, its stakeholders and most importantly its patients.
Subscribe to The Syneos Health Podcast: Early Signals for new episodes.
If there’s a topic you’d like us to explore, send us a message at [email protected].
For more actionable, future-focused life sciences insights, visit the Syneos Health Insights Hub.
Episodi
- Can We Redefine Cancer by Its Biology? · 19 minWhat if the future of oncology is defined not by where a tumor originates, but by the molecular biology driving it? In this episode of Early Signals, recorded at ASCO 2026, Wael…
- Early Signals at ASCO 2026 | Can Real-World Evidence Bring Research Closer to Patients? · 20 minCan real-world evidence do more than support regulatory decisions? Could it fundamentally change how clinical research is designed, delivered and connected to patient care? In…
- Early Signals at ASCO 2026 | Beyond Digitization: How AI Is Transforming Clinical Trial Operations · 35 minIf clinical trials are already digitized, why do clinical operations remain so complex, manual and resource-intensive? In this episode of Early Signals, Wael Harb, MD, speaks…
- Early Signals at ASCO 2026 | Can TIL Therapy Reach More Patients? · 19 minCan the next generation of tumor-infiltrating lymphocyte (TIL) therapies overcome the barriers that have limited broader adoption of cell therapy in solid tumors? In this episode…
- Early Signals at ASCO 2026 | Is MRD Ready to Guide Drug Development? · 25 minCan minimal residual disease (MRD) do more than measure response? Could it redefine how multiple myeloma therapies are developed, approved and ultimately used to guide patient…
- Early Signals at ASCO 2026 | Can AI Predict Cancer's Next Move? Rethinking Drug Resistance in Oncology · 24 minCan AI predict cancer's next move before drug resistance develops? Drug resistance remains one of the greatest challenges in oncology drug development. Most targeted therapies…
- Early Signals at ASCO 2026 | AI, Multimodal Data and the Next Era of Precision Oncology · 26 minWhat if artificial intelligence could help remove the uncertainty from cancer treatment decisions? Precision oncology has already transformed cancer care by matching therapies to…
- Early Signals at ASCO 2026 | Can AI Finally Rebuild Clinical Research? · 41 minLess than 5% of patients participate in clinical trials today; a statistic that has remained virtually unchanged for more than two decades despite massive advances in science and…
- Early Signals at ASCO 2026 | How Do You Turn Next-Generation ADC Science Into Global Clinical Success? · 18 minAntibody-drug conjugates (ADCs) are transforming oncology, but scientific innovation alone isn't enough. As platforms become more sophisticated—with novel linker technologies…
- Early Signals at ASCO 2026 | Reigniting Response: How Oncolytic Viruses May Reshape Ovarian Cancer Treatment · 15 minWhat happens when an established treatment regains its effectiveness against resistant disease? In this episode of the Syneos Health Podcast: Early Signals, Wael Harb, MD, Head…
- Early Signals at ASCO 2026 | Creating a New Therapeutic Class: The Promise of Direct MYC Inhibition · 41 minCan MYC finally be drugged? Learn how MycRx is advancing a direct MYC inhibitor and navigating the science and business of oncology innovation. What if one of cancer's most…
- Welcome to Early Signals! · 1 minWhat are the signals today that will define the future of oncology treatment tomorrow? The Syneos Health Podcast: Early Signals brings together leaders across biopharma…
- Project Optimus Series | Clinical Pharmacology and Project Optimus · 19 minWe continue our Project Optimus series with a focus on clinical pharmacology—a foundational element in redefining dose optimization in oncology drug development. Dr. Wael Harb is…
- Project Optimus Series | The Role of Biostatistics · 17 minAs regulatory expectations evolve under the FDA’s Project Optimus oncology dosing initiative, biostatistics is emerging as a central pillar in designing and executing trials that…
- Project Optimus Series | Operationalizing Dose Optimization · 18 minIn this episode, we continue our exploration of Project Optimus and the evolution of dose optimization in oncology drug development. Following our discussion on regulatory…
- Project Optimus Series | The Regulatory Implications of Project Optimus · 19 minIn this episode, Dr. Wael Harb, Vice President of Medical Management at Syneos Health, continues the exploration of FDA's groundbreaking Project Optimus and its profound…
- Project Optimus Series | Navigating the Realities of Project Optimus · 21 minLaunched in 2021 by the FDA's Oncology Center of Excellence, Project Optimus seeks to reshape traditional oncology trial designs and dosing paradigms, shifting from maximum…








